LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 2900

Search options

  1. Article: [MANAGEMENT OF DRUG ALLERGY-AN UPDATE].

    Yamaguchi, Masao

    Arerugi = [Allergy

    2021  Volume 70, Issue 2, Page(s) 75–79

    MeSH term(s) Anaphylaxis ; Desensitization, Immunologic ; Drug Hypersensitivity/therapy ; Humans
    Language Japanese
    Publishing date 2021-03-04
    Publishing country Japan
    Document type Journal Article
    ZDB-ID 974201-3
    ISSN 0021-4884
    ISSN 0021-4884
    DOI 10.15036/arerugi.70.75
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: [ASTHMA PREVENTION AND MANAGEMENT GUIDELINE 2018].

    Yamaguchi, Masao

    Arerugi = [Allergy

    2021  Volume 70, Issue 4, Page(s) 271–273

    MeSH term(s) Asthma/prevention & control ; Cytokines ; Humans ; Immunity, Innate ; Lymphocytes ; Th2 Cells
    Chemical Substances Cytokines
    Language Japanese
    Publishing date 2021-06-17
    Publishing country Japan
    Document type Journal Article
    ZDB-ID 974201-3
    ISSN 0021-4884
    ISSN 0021-4884
    DOI 10.15036/arerugi.70.271
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: [UTILIZATION OF BASOPHIL ACTIVATION TEST IN ALLERGIC DISEASE DIAGNOSIS].

    Suzukawa, Maho / Yamaguchi, Masao

    Arerugi = [Allergy

    2022  Volume 71, Issue 9, Page(s) 1115–1121

    MeSH term(s) Humans ; Basophil Degranulation Test ; Hypersensitivity/diagnosis ; Basophils
    Language Japanese
    Publishing date 2022-11-12
    Publishing country Japan
    Document type Journal Article
    ZDB-ID 974201-3
    ISSN 0021-4884
    ISSN 0021-4884
    DOI 10.15036/arerugi.71.1115
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Comparison of comfort and tear stability with two novel silicone-hydrogel daily disposable contact lenses.

    Mimura, Tatsuya / Noma, Hidetaka / Yamaguchi, Masao / Shinbo, Koichiro

    International ophthalmology

    2024  Volume 44, Issue 1, Page(s) 136

    Abstract: Background: The surface wettability of soft contact lenses (SCLs) affects the wearing comfort. Verofilcon A is a daily disposable silicone hydrogel contact lens with SMARTSURFACE® technology, ensuring high surface wettability.: Purpose: To evaluate ... ...

    Abstract Background: The surface wettability of soft contact lenses (SCLs) affects the wearing comfort. Verofilcon A is a daily disposable silicone hydrogel contact lens with SMARTSURFACE® technology, ensuring high surface wettability.
    Purpose: To evaluate tear stability on the surface of verofilcon A and narafilcon A SCLs and correlate these findings with clinical parameters and patients' discomfort.
    Methods: Sixty-two SCL wearers (124 eyes) with SCL discomfort were randomly assigned to use narafilcon A (control SCL) and verofilcon A for 2 weeks each by crossover. The noninvasive tear break-up time (NIBUT) of the naked eye at baseline and pre-lens NIBUT (PL-NIBUT) of the SCL surface after 2 weeks of using each SCL were measured using the DR-1α® dry eye observation device. Corneal superficial punctate keratopathy (SPK) (0-3) and conjunctival hyperemia (0-3), and comfort level of SCL wear (1-10) were also evaluated.
    Results: NIBUT and PL-NIBUT values were 4.6 ± 2.3 s for the naked eye, 6.6 ± 6.6 s for narafilcon A, and 11.3 ± 3.5 s for verofilcon A. verofilcon A had significantly higher PL-NIBUT than the naked eye and narafilcon A (p < 0.05). SPK (0.16 ± 0.48 vs. 0.00 ± 0.00, p < 0.01) and conjunctival hyperemia (1.15 ± 0.82 vs. 0.49 ± 0.50, p < 0.01) scores were lower when wearing verofilcon A than narafilcon A. The ocular comfort score of wearing SCLs was higher with verofilcon A than with narafilcon A (8.7 ± 1.8 vs. 9.8 ± 0.5, p < 0.01). The ocular comfort score for wearing verofilcon A was higher, regardless of the baseline NIBUT.
    Conclusion: The results of this study showed a consistent surface-wetting advantage of verofilcon A in patients with ocular discomfort. verofilcon A was used comfortably in patients with low NIBUT scores at baseline. The findings suggest that verofilcon A is recommended for SCL wearers experiencing SCL-related dry eye symptoms and discomfort.
    MeSH term(s) Humans ; Hydrogels ; Silicones ; Hyperemia ; Contact Lenses, Hydrophilic ; Dry Eye Syndromes/etiology ; Tears
    Chemical Substances Hydrogels ; Silicones
    Language English
    Publishing date 2024-03-14
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 800087-6
    ISSN 1573-2630 ; 0165-5701
    ISSN (online) 1573-2630
    ISSN 0165-5701
    DOI 10.1007/s10792-024-03075-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: [The Front-line of Drug Allergy].

    Yamaguchi, Masao

    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine

    2018  Volume 105, Issue 8, Page(s) 1451–1454

    MeSH term(s) Anaphylaxis ; Drug Hypersensitivity/prevention & control ; Humans ; Severity of Illness Index
    Language Japanese
    Publishing date 2018-09-23
    Publishing country Japan
    Document type Journal Article
    ZDB-ID 952816-7
    ISSN 1883-2083 ; 0021-5384
    ISSN (online) 1883-2083
    ISSN 0021-5384
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: [ANAPHYLAXIS TRIGGERED BY RADIOCONTRAST MEDIA AND LOCAL ANESTHETICS; WHAT SHOULD BE DONE WHEN THEY ARE ESSENTIAL?]

    Yamaguchi, Masao

    Arerugi = [Allergy

    2018  Volume 67, Issue 2, Page(s) 98–101

    MeSH term(s) Anaphylaxis/chemically induced ; Anesthetics, Local/adverse effects ; Contrast Media/adverse effects ; Drug Hypersensitivity ; Humans
    Chemical Substances Anesthetics, Local ; Contrast Media
    Language Japanese
    Publishing date 2018-03-16
    Publishing country Japan
    Document type Journal Article
    ZDB-ID 974201-3
    ISSN 0021-4884
    ISSN 0021-4884
    DOI 10.15036/arerugi.67.98
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: [Clinical practice for total care of allergic diseases. Topics: VIII. Advanced Lecture: Front-line Therapy for Allergic Diseases: Immunotherapy and Molecular Target Therapy].

    Yamaguchi, Masao

    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine

    2018  Volume 105, Issue 10, Page(s) 1983–1988

    MeSH term(s) Allergens/immunology ; Humans ; Hypersensitivity/immunology ; Hypersensitivity/therapy ; Immunoglobulin E/immunology ; Immunotherapy ; Molecular Targeted Therapy
    Chemical Substances Allergens ; Immunoglobulin E (37341-29-0)
    Language Japanese
    Publishing date 2018-09-04
    Publishing country Japan
    Document type Journal Article
    ZDB-ID 952816-7
    ISSN 1883-2083 ; 0021-5384
    ISSN (online) 1883-2083
    ISSN 0021-5384
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: GUIDELINE FOR OCCUPATIONAL ALLERGIC DISEASES-ANTICIPATING A NEW, 2016-VERSION.

    Yamaguchi, Masao

    Arerugi = [Allergy

    2016  Volume 65, Issue 6, Page(s) 753–756

    MeSH term(s) Humans ; Hypersensitivity/diagnosis ; Hypersensitivity/therapy ; Occupational Diseases/diagnosis ; Occupational Diseases/therapy ; Practice Guidelines as Topic
    Language Japanese
    Publishing date 2016
    Publishing country Japan
    Document type Journal Article
    ZDB-ID 974201-3
    ISSN 0021-4884
    ISSN 0021-4884
    DOI 10.15036/arerugi.65.753
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: ADULT ANAPHYLAXIS.

    Yamaguchi, Masao

    Arerugi = [Allergy

    2016  Volume 65, Issue 10, Page(s) 1243–1247

    MeSH term(s) Adult ; Anaphylaxis/epidemiology ; Anaphylaxis/etiology ; Asthma/complications ; Desensitization, Immunologic ; Female ; Humans ; Male ; Menopause ; Middle Aged ; Risk Factors
    Language Japanese
    Publishing date 2016
    Publishing country Japan
    Document type Journal Article
    ZDB-ID 974201-3
    ISSN 0021-4884
    ISSN 0021-4884
    DOI 10.15036/arerugi.65.1243
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Real-World Safety and Effectiveness of Benralizumab in Japanese Patients with Severe Asthma: A Multicenter Prospective Observational Study.

    Yamaguchi, Masao / Nishimura, Yoshihiro / Takumi, Yuko / Hayashi, Nobuya / Sakamoto, Kei / Tohda, Yuji

    Journal of asthma and allergy

    2024  Volume 17, Page(s) 45–60

    Abstract: Introduction: This study aimed to demonstrate whether benralizumab maintained the safety and effectiveness profiles established in randomized controlled trials among all patients with severe uncontrolled asthma initially prescribed benralizumab in the ... ...

    Abstract Introduction: This study aimed to demonstrate whether benralizumab maintained the safety and effectiveness profiles established in randomized controlled trials among all patients with severe uncontrolled asthma initially prescribed benralizumab in the real-world setting in Japan.
    Methods: This was a prospective, observational, multicenter post-marketing study (ClinicalTrial.gov, NCT03588546). The safety and tolerability of benralizumab over 1 year were assessed by the incidence of adverse events (AEs), serious AEs, adverse drug reactions (ADRs), and serious ADRs. Patient background characteristics indicating a more frequent onset of ADRs with benralizumab were explored. The main effectiveness assessment was the change in Asthma Control Questionnaire-5 (ACQ-5) score from baseline. Patients with baseline ACQ-5 scores ≥1.5 were defined as having severe uncontrolled asthma.
    Results: In total, 632 patients were evaluated for safety and 274 for effectiveness; 139 patients were included in the severe uncontrolled asthma subgroup. ADRs were reported in 12.7% and serious AEs in 13.0% of patients. Serious infections occurred in 3.8%, serious hypersensitivity in 0.3%, and malignancy in 0.3% of patients. No helminthic infections occurred. In the effectiveness population, benralizumab improved the mean (standard deviation [95% confidence interval]) ACQ-5 score by -1.16 (1.40 [-1.36, -0.96]) from baseline; forced expiratory volume in 1 second by 0.151 (0.440 [0.09, 0.21]) L; and Mini-Asthma Quality of Life questionnaire score by 1.16 (1.29 [0.94, 1.38]) at the last observation. The annual asthma exacerbation rate was 0.42. A greater ACQ-5 score improvement was observed among patients with eosinophilic asthma characteristics.
    Conclusion: No new safety concerns were raised, and patients experienced benefits consistent with previous studies of benralizumab, thus supporting the use of benralizumab for the add-on maintenance treatment of patients with eosinophilic severe uncontrolled asthma.
    Language English
    Publishing date 2024-01-20
    Publishing country New Zealand
    Document type Journal Article
    ZDB-ID 2494877-9
    ISSN 1178-6965
    ISSN 1178-6965
    DOI 10.2147/JAA.S432695
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top